Each day, normal human cell tissues express a protein known as p53 that wages war against potential malignancies. However, between 30 and 40 percent of human breast cancers express a defective (mutant) form of p53 that helps ...
Mar 26, 2018
0
11
(HealthDay)—For patients with diabetic macular edema, repeated ranibizumab treatment does not appear to be associated with impaired macular perfusion, according to a study published online March 1 in JAMA Ophthalmology.
Mar 7, 2018
0
12
A new study led by vision researchers at the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo and VA Western New York Healthcare System has demonstrated that the addition of widely available ...
Feb 5, 2018
0
8
(HealthDay)—Hematopoietic stem/progenitor cell (HSPC)-derived chimeric antigen receptor (CAR) T-cells are capable of long-term engraftment in a model of HIV/AIDS, according to a study published online Dec. 28 in PLOS Pathogens.
Jan 3, 2018
0
1
A new review provides guidance on a deadly, but rare, disease that is potentially curable if identified early. Severe combined immunodeficiency disease (SCID), known as the "bubble boy disease" in the 1970s, is treatable ...
Dec 18, 2017
0
18
(HealthDay)—In patients with progressive glioblastoma, treatment with lomustine plus bevacizumab does not confer a survival advantage over treatment with lomustine alone, according to a study published online Nov. 15 in ...
Nov 17, 2017
0
0
(HealthDay)—HIV-positive individuals treated with combination antiretroviral therapy (cART) have poorer neuropsychological test scores than controls but no significant neuropsychological decline over time, according to ...
Nov 15, 2017
0
1
(HealthDay)—For patients with inflammatory bowel disease (IBD), the risk of lymphoma is increased with use of thiopurine monotherapy, anti-tumor necrosis factor (TNF) monotherapy, and combination therapy, according to a ...
Nov 8, 2017
0
0
A combination of two antibiotics is often prescribed to treat community-acquired pneumonia in children but a JAMA Pediatrics study is now showing that using just one of the two has the same benefit to patients in most cases.
Nov 1, 2017
0
0
(HealthDay)—Combination therapy consisting of ranibizumab plus verteporfin photodynamic therapy (vPDT) is superior to ranibizumab monotherapy for treatment of eyes with polypoidal choroidal vasculopathy (PCV), according ...
Oct 9, 2017
0
0
